Literature DB >> 29710129

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy.

Inmaculada Hernandez1,2, Vinay Prasad3,4,5, Walid F Gellad2,6.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29710129      PMCID： PMC6145722          DOI： 10.1001/jamaoncol.2018.0977

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  3 in total

1.  The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.

Authors:  Robert Hettle; Mark Corbett; Sebastian Hinde; Robert Hodgson; Julie Jones-Diette; Nerys Woolacott; Stephen Palmer
Journal:  Health Technol Assess       Date:  2017-02       Impact factor: 4.014

2.  A Comparison of Costs Between Medical and Surgical Patients in an Academic Pediatric Intensive Care Unit.

Authors:  Benson S Hsu; Thomas B Brazelton
Journal:  WMJ       Date:  2015-12

3.  Professional Fee Ratios for US Hospital Discharge Data.

Authors:  Cora Peterson; Likang Xu; Curtis Florence; Scott D Grosse; Joseph L Annest
Journal:  Med Care       Date:  2015-10       Impact factor: 2.983
  3 in total
  22 in total

1.  Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial.

Authors:  Jeremy S Abramson; Tanya Siddiqi; Jacob Garcia; Christine Dehner; Yeonhee Kim; Andy Nguyen; Sophie Snyder; November McGarvey; Matthew Gitlin; Corey Pelletier; Monika P Jun
Journal:  Blood Adv       Date:  2021-03-23

Review 2.  Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.

Authors:  Rajshekhar Chakraborty; Surbhi Sidana; Gunjan L Shah; Michael Scordo; Betty K Hamilton; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-28       Impact factor: 5.742

3.  Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland.

Authors:  Maziar Moradi-Lakeh; Mohsen Yaghoubi; Patrick Seitz; Mehdi Javanbakht; Elisabeth Brock
Journal:  Adv Ther       Date:  2021-05-22       Impact factor: 3.845

Review 4.  Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know.

Authors:  H A Valand; F Huda; R K Tu
Journal:  AJNR Am J Neuroradiol       Date:  2019-05-02       Impact factor: 3.825

5.  Missing Conflict of Interest Disclosure.

Authors: 
Journal:  JAMA Oncol       Date:  2018-10-01       Impact factor: 31.777

Review 6.  Value and affordability of CAR T-cell therapy in the United States.

Authors:  Salvatore Fiorenza; David S Ritchie; Scott D Ramsey; Cameron J Turtle; Joshua A Roth
Journal:  Bone Marrow Transplant       Date:  2020-05-30       Impact factor: 5.483

Review 7.  Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.

Authors:  Leila Amini; Sara K Silbert; Nirali N Shah; Mohamed Abou-El-Enein; Shannon L Maude; Loretta J Nastoupil; Carlos A Ramos; Renier J Brentjens; Craig S Sauter
Journal:  Nat Rev Clin Oncol       Date:  2022-03-22       Impact factor: 66.675

Review 8.  Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Authors:  Miguel-Angel Perales; Larry D Anderson; Tania Jain; Saad S Kenderian; Olalekan O Oluwole; Gunjan L Shah; Jakub Svoboda; Mehdi Hamadani
Journal:  Transplant Cell Ther       Date:  2022-06-26

Review 9.  Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy.

Authors:  Shota Aoyama; Ryosuke Nakagawa; James J Mulé; Adam W Mailloux
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

Review 10.  Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.

Authors:  Lele Miao; Zhengchao Zhang; Zhijian Ren; Futian Tang; Yumin Li
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.